Colon cancer has an image problem. Rather, colon cancer screening has an image problem.
The phrase “I’d rather have a colonoscopy than …” has become a go-to for those looking to make a point about an undesirable activity. But few are saying the obvious: That they would rather have a colonoscopy—an uncomfortable but painless procedure that is one of the most sensitive tests to screen for colon cancer — than undergo treatment for colon cancer.1 Colonoscopies and other colorectal screening methods won’t kill anyone. Colon cancer itself? That’s a different story.
How common is colon cancer?
Colorectal cancer is the second most common cause of cancer deaths among men and women combined in the United States.2 Over a lifetime, there’s roughly a 4% risk of developing colorectal cancer, and while cases have dropped overall since the 1980s, rates among people younger than 50 actually rose by 2% every year from 2012 to 2016.2
The disease may be widespread, but it doesn’t strike equally. Indigenous communities have higher rates of colorectal cancer than white people, and people of Eastern European Jewish descent have one of the highest risks of colorectal cancer of any ethnic group in the world.3
Among the Black community, the risk is both widespread and elevated — Black Americans are roughly 20% more likely to develop colorectal cancer than other ethnic groups and are 40% more likely to die from it.3
Despite these differences, the biggest barrier shared by Americans at large is a lack of screening and preventive care.4
Colon cancer screening is crucial — but 31% of adults aren’t up to date5
Sixty percent of colorectal cancer deaths could be prevented with screening, a test whose costs are protected by the Affordable Care Act.3,6 Yet between the “ew” factor of the most popular screenings — colonoscopies and stool tests — and misconceptions about personal risk, preventive care often gets pushed aside.
One of the issues that keeps people from scheduling a screening — the fact that the earliest stages of colon cancer have few if any symptoms — is exactly why screening is essential.7 Screening rates have increased over time — in fact, nearly 69% of adults ages 50 to 75 were up to date as of 2018.5 But screening rates plummeted during the onset of the COVID-19 pandemic. And though rates have largely rebounded, colorectal cancer screenings still need to increase by 50% to return to pre-pandemic levels.8
You can help protect your workforce with one simple step
The lack of screening adds up in a major way — colorectal cancer has the second-highest cost of all cancers in the United States, totaling $14.1 billion in annual medical expenses.9 That takes a toll on families struggling to find a way to cover out-of-pocket costs, years of treatment and recovery, and the mental strain associated with fighting a deadly condition.
Health insurance covers part of those costs, but even a well-designed plan leaves large gaps that need to be covered out of pocket. Offering cancer insurance to your workforce can give you and your employees peace of mind, helping to ensure that if your employees are diagnosed with cancer, they can pay for treatment more easily and focus on recovery instead of mounting costs. But you can also offer them a more proactive form of protection — just by offering specific Aflac plans.
Some Aflac insurance plans — including critical illness, accident and hospital coverage — may include wellness benefits, paying your employees for out-of-pocket expenses that could include health screening tests performed as a part of preventive care, such as diagnostic procedures like colonoscopies. And this protection can come at little or no cost to you.
You might not be able to get your workforce to shake off the jokes about colonoscopies. What you can do is give them an incentive to help make sure they receive proper preventive care … and a cushion of protection to help when they need it.
Ready to help protect your workforce against cancer? Contact your Aflac benefits advisor or visit Aflac.com/business.
Companies choose to make Aflac policies available to increase benefits options without impacting their bottom line.
1 Mayo Clinic. “Colon cancer screening: Weighing the options.” Published 3.26.2021. Accessed 1.25.2023.
2 American Cancer Society. “Key Statistics for Colorectal Cancer.” Revised 1.12.2022. Accessed 1.25.2023.
3 Fight Colorectal Cancer. “Facts and Stats.” Accessed 1.25.2023.
4 American Cancer Society. Can Colorectal Polyps and Cancer Be Found Early? Accessed 1.25.2023.
5 Centers for Disease Control and Prevention. “Colorectal Cancer Statistics.” Reviewed 6.8.2021. Accessed 1.25.2023.
6 American Cancer Society. “Insurance Coverage for Colorectal Cancer Screening.” Revised 5.19.2021. Accessed 1.25.2023.
7 Mayo Clinic. “Colon cancer.” Published 6.11.2021. Accessed 1.25.2023.
8 Healthcare. “Impact of the COVID-19 Pandemic on Colorectal and Prostate Cancer Screening in a Large U.S. Health System.” Published 1.29.2022. Accessed 1.25.2023.
9 Centers for Disease Control and Prevention. “Cost-Effectiveness of Colorectal Cancer Interventions.” Reviewed 8.18.2021. Accessed 1.25.2023.
Cancer: In Idaho, Policies B70100ID, B70200ID, B70300ID, B7010EPID, B7020EPID. In Oklahoma, Policies B70100OK, B70200OK, B70300OK, B7010EPOK, B7020EPOK. Not available in VA. Critical Illness: In Oklahoma, Policies B71100OK & B7110HOK. Not available in ID, NJ, NY & VA. Hospital: In Idaho, Policies B40100ID & B4010HID. In Oklahoma, Policies B40100OK & B4010HOK. Not available in VA.
This is a brief product overview only. Coverage may not be available in all states including but not limited to New York, New Jersey, New Mexico & Virginia. Benefits/premium rates may vary based on plan selected. Optional riders are available at an additional cost. The policy has limitations and exclusions that may affect benefits payable. Refer to the policy for complete details, limitations, and exclusions. For costs and complete details of the coverage, please contact your local Aflac agent.
Coverage is underwritten by Aflac. In New York, coverage is underwritten by Aflac New York.
Aflac WWHQ | 1932 Wynnton Road | Columbus, GA 31999
Z2200198R1
EXP 1/24